Crystal Intentions: A Design-Integrated Roadmap for Engineering the Solid-State Properties of Active Pharmaceutical Ingredients

Every crystal an active pharmaceutical ingredient (API) forms carries an intention, whether or not that intention was deliberately engineered: a lattice, hydrate shell, or amorphous halo that predetermines solubility, dissolution rate, physical and chemical stability, mechanical processability, and ultimately oral bioavailability long before the molecule reaches the bloodstream. This review proposes and applies a landscape-based organizing framework in which solid-state form is treated as an occupied position on a multidimensional lattice free-energy surface, and every deliberate engineering strategy polymorph and hydrate control, salt formation, cocrystallization, amorphous and co-amorphous dispersion, and particle/crystal habit engineering is positioned along two orthogonal axes: thermodynamic depth (resistance to reversion) and kinetic accessibility (ease with which the form can be reached and manufactured reproducibly). Framed this way, polymorph screening becomes a search for deep, accessible minima; salts and cocrystals become supramolecular relocations of the API onto an entirely different multicomponent landscape; amorphous dispersions become a deliberate exchange of thermodynamic depth for kinetic height, stabilized by polymeric or low-molecular-weight co-formers through the spring-and-parachute mechanism; and particle engineering becomes a second, independent landscape operating at the mesoscale rather than the molecular scale. We synthesize thirty-nine studies published since 2020 to update the mechanistic, analytical, and computational toolkit available to navigate this landscape, with particular emphasis on crystal structure prediction (CSP) using machine-learned interatomic potentials, machine-learning-guided coformer and amorphous-dispersion screening, disproportionation risk modeling for pharmaceutical salts, spherical co-crystallization for simultaneous molecular- and particle-level design, and continuous, solvent-minimized crystallization platforms aligned with ICH Q13. Original comparative figures and tables translate this landscape framework into a decision architecture Solid-State-by-Design (SSbD) intended to guide form selection from first candidate nomination through commercial manufacture, converting an API's crystal intentions from an accident of discovery-stage crystallization into a deliberately engineered design outcome. We close by identifying unresolved landscape-navigation problems: long-term prediction of amorphous recrystallization risk, extension of CSP and machine-learning tools to larger and more conformationally flexible discovery-stage molecules, and tighter integration of computational screening into candidate selection itself, rather than only after a lead has already been chosen.